Latest news with #Roivant
Time of India
8 hours ago
- Business
- Time of India
'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months
Vivek Ramaswamy breaks record in raising fund for Ohio Governor election which will be held in November 2026. Vivek Ramaswamy has raised over $8.5 million since his announcement of Ohio Governor election bid from the Republican party following his exit from the Department of Government Efficiency. Axios reported that this much money this early in the election cycle with the primary nearly a full year away is record-breaking. For comparison, Axios reported that Gov. Mike DeWine raised $3 million in the first half of 2021 during his reelection campaign. This money does not include any personal financing from Ramaswamy who spent over $30 million of his own money to fund his presidential campaign which he withdrew to support Donald Trump. "Just the beginning of breaking records in Ohio," Vivek reacted to his fund news. What is Vivek Ramaswamy's net worth? What is his source of wealth? Vivek Ramaswamy's net worth in 2025 is estimated to be between $800 million and $1.1 billion, with most sources leaning toward the higher end, around $1 billion. His wealth primarily comes from his 7-11% stake in Roivant Sciences, a biotech company he founded in 2014, valued at over $840 million based on SEC filings and campaign disclosures. Additional wealth stems from his stake in Strive Asset Management (worth over $100 million), investments in stocks, bonds, cryptocurrencies, and real estate, including two Ohio homes valued at $2.5 million. How did Indian-origin Vivek Ramaswamy become so rich? Born in 1985 to Indian immigrant parents (his father was a General Electric engineer and attorney, his mother a psychiatrist), Ramaswamy grew up in the Cincinnati suburb of Evendale. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trading CFD dengan Teknologi dan Kecepatan Lebih Baik IC Markets Mendaftar Undo He attended St. Xavier High School, graduating as valedictorian in 2003. With his early business acumen, Vivek while he was studying biology at Harvard co-founded a business, a tech startup that connected budding entrepreneurs with professional resources via the internet. The business was later sold to the Kauffman Foundation, a nonprofit that fosters entrepreneurs and education. After graduating from Harvard, Ramaswamy joined QVT Financial, a New York-based investment advisory firm and hedge fund manager. He also studied law at Yale University in the same batch as JD Vance. His work at QVT involved investing in biotech companies, which led to his interest in the development of new prescription drugs. Ramaswamy founded Roivant in 2014 to buy or license promising drugs that weren't a priority for their owners. Roivant would then take over the development process for the potential future medicine. The company organized its developing drugs into subsidiary companies that could be spun off into separate ventures or be sold. In 2015, Ramaswamy cashed out a piece of his Roivant stake, accounting for the majority of his nearly $37.1 million in capital gains on his tax return. A potential Alzheimer's Disease drug, called intepirdine, was the main drug under development at Axovant, a Roivant subsidiary that the company spun off in a 2015 initial public offering. The stock nearly doubled in price on the first day of trading, making the company worth nearly $3 billion. In 2021, Ramaswamy stepped down as CEO and chairman of Roivant as he pursued new ventures. Then he published his best-selling book 'Woke Inc'
Yahoo
09-06-2025
- Business
- Yahoo
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM. To access the video conference, please register online using this registration link. The presentation and conference details will also be available under 'Events & Presentations' in the Investors section of the Roivant website at The archived webcast will be available on Roivant's website after the conference call. About Priovant Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib is able to distinctively suppress key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted therapy. Brepocitinib is administered as a once-daily oral therapy. It has been dosed in over 1,400 subjects and has generated positive data in seven Phase 2 studies. Brepocitinib is currently being evaluated in dermatomyositis (Phase 3), non-infectious uveitis (Phase 3), and cutaneous sarcoidosis (Phase 2). About Roivant Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit Roivant Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are usually identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts:InvestorsKeyur MediaStephanie ResearchDaniel Herz-Roiphe
Yahoo
09-06-2025
- Business
- Yahoo
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM. To access the video conference, please register online using this registration link. The presentation and conference details will also be available under 'Events & Presentations' in the Investors section of the Roivant website at The archived webcast will be available on Roivant's website after the conference call. About Priovant Priovant Therapeutics is a biotechnology company dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset is brepocitinib, a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib is able to distinctively suppress key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12, and IL-23—with a single, targeted therapy. Brepocitinib is administered as a once-daily oral therapy. It has been dosed in over 1,400 subjects and has generated positive data in seven Phase 2 studies. Brepocitinib is currently being evaluated in dermatomyositis (Phase 3), non-infectious uveitis (Phase 3), and cutaneous sarcoidosis (Phase 2). About Roivant Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit Roivant Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are usually identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts:InvestorsKeyur MediaStephanie ResearchDaniel Herz-Roiphe in to access your portfolio
